Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesChetan Bettegowda, Jon Weingart, Mark Sausen et al.|Science Translational Medicine|2014Cited by 5.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore‐Bianchi, Salvatore Siena, Calogero Lauricella et al.|The Lancet Oncology|2016Cited by 1k
The genomic landscape of response to EGFR blockade in colorectal cancerAndrea Bertotti, Victor E. Velculescu, Eniko Papp et al.|Nature|2015Cited by 495
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trialSalvatore Siena, Takayuki Yoshino, Maria Di Bartolomeo et al.|The Lancet Oncology|2021Cited by 411
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsGiovanni Fucà, Filippo Pietrantonio, Vincenzo Guarini et al.|British Journal of Cancer|2020Cited by 350